| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 55513-0037-04 | 55513-0037 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Feb 18, 2011 | Nov 30, 2008 | No Longer Used | |||
| 00093-7485-20 | 00093-7485 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 2, 2008 | Sep 30, 2019 | No Longer Used |
| 55154-7832-05 | 55154-7832 | Metoclopramide | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Jul 9, 2025 | In Use | |
| 55513-0267-01 | 55513-0267 | Epoetin alfa | Epogen | 3000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Apr 30, 1990 | In Use | ||
| 62756-0131-01 | 62756-0131 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use | |
| 25021-0826-87 | 25021-0826 | Zoledronic Acid | Zoledronic Acid | 0.04 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Apr 15, 2025 | In Use | ||
| 57237-0078-30 | 57237-0078 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 12, 2010 | In Use | |
| 68071-1710-03 | 68071-1710 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jun 9, 2017 | Dec 31, 2019 | No Longer Used |
| 82737-0073-01 | 82737-0073 | Motixafortide | Aphexda | 62.0 mg/1.7mL | Ancillary Therapy | Immunostimulant | Stem cell mobilizer | Subcutaneous | Sep 8, 2023 | In Use | |
| 55390-0148-01 | 55390-0148 | Granisetron Hydrochloride | Granisetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oct 28, 2014 | Nov 30, 2009 | No Longer Used | ||
| 68084-0220-01 | 68084-0220 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 21, 2023 | In Use | |
| 50090-2103-00 | 50090-2103 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 14, 2015 | Jan 31, 2019 | In Use |
| 00173-0712-02 | 00173-0712 | Dutasteride | Avodart | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec 10, 2002 | Apr 30, 2018 | No Longer Used |
| 54868-2523-01 | 54868-2523 | Erythropoietin | Procrit | 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug 11, 1994 | In Use | ||
| 00378-8172-91 | 00378-8172 | Dronabinol | Dronabinol | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Nov 1, 2011 | May 31, 2016 | No Longer Used |
| 43063-0560-20 | 43063-0560 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 12, 2015 | Jan 18, 2021 | No Longer Used |
| 70625-0311-01 | 70625-0311 | FOSAPREPITANT | FOSAPREPITANT | 150.0 mg/mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Nov 3, 2021 | In Use | |
| 63629-1585-03 | 63629-1585 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Oct 30, 2007 | Feb 28, 2017 | No Longer Used |
| 58118-7500-08 | 58118-7500 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 13, 2018 | In Use | |
| 54288-0183-01 | 54288-0183 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Jun 5, 2025 | In Use | ||
| 68462-0106-33 | 68462-0106 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use | |
| 65293-0373-25 | 65293-0373 | ONDANSETRON HYDROCHLORIDE | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov 18, 2009 | Jan 31, 2015 | In Use |
| 69539-0034-01 | 69539-0034 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sep 5, 2019 | In Use | |
| 50090-2285-00 | 50090-2285 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan 12, 2016 | Dec 31, 2019 | In Use |
| 70518-1551-02 | 70518-1551 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 21, 2023 | In Use |
Found 11888 results — Export these results
Home